title: Ifosfamide-induced renal tubular defect.
abstract: We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m2/course over 2 days in children with a diagnosis of malignant mesenchymal tumors. This adverse effect could be minimized dividing dosage of the drug. However at present it is not clear if divided doses are completely safe.
authors.affiliation: Department of Pediatric Hematology-Oncology, Social Security Hospital 12 de Octubre, Madrid, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Torres Valdivieso
authors.forename: J
authors.initials: J
authors.lastname: López Pérez
authors.forename: C
authors.initials: C
authors.lastname: Melero
authors.forename: J L
authors.initials: JL
authors.lastname: Vivanco
authors.forename: R
authors.initials: R
authors.lastname: Muley
authors.forename: J
authors.initials: J
authors.lastname: Vara
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide